Loading cancer entity…
Loading cancer entity…
Clinical trials
8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,290)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05228249 | Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 13, 2023 | clinicaltrials |
| NCT00995059 | Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | Mayo ClinicOTHER | 0 | Jan 5, 2023 | clinicaltrials |
| NCT04639843 | Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Nov 4, 2022 | clinicaltrials |
| NCT04635683 | Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma | withdrawn | Phase 1 | 0 | Yazeed SawalhaOTHER | 0 | Sep 30, 2022 | clinicaltrials |
| NCT04998747 | A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)(ProxiMMity-1) | withdrawn | Phase 1 | 0 | AmgenINDUSTRY | 0 | Sep 27, 2022 | clinicaltrials |
| NCT03768310 | CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA) | withdrawn | Phase 1 | 0 | Baylor College of MedicineOTHER | 1 | Jul 21, 2022 | clinicaltrials |
| NCT04836832 | Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma | withdrawn | Phase 1 | 0 | Narendranath EpperlaOTHER | 0 | Jun 7, 2022 | clinicaltrials |
| NCT02847949 | A Study of IGN002 for Refractory NHL | withdrawn | Phase 1 | 0 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Mar 11, 2022 | clinicaltrials |
| NCT04918511 | A Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed Refractory Multiple Myeloma(COAST) | withdrawn | Phase 1 | 0 | Oncopeptides ABINDUSTRY | 1 | Nov 26, 2021 | clinicaltrials |
| NCT03639324 | Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL(RIVe-CLL/SLL) | withdrawn | Phase 1 | 0 | Virginia Commonwealth UniversityOTHER | 0 | Nov 9, 2021 | clinicaltrials |
| NCT04464889 | HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation | withdrawn | Phase 1 | 0 | Medigene AGINDUSTRY | 1 | Oct 8, 2021 | clinicaltrials |
| NCT01101581 | Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL | withdrawn | Phase 1 / Phase 2 | 0 | Gilead SciencesINDUSTRY | 1 | Aug 18, 2021 | clinicaltrials |
| NCT03873025 | A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma(PLACARD) | withdrawn | Phase 1 / Phase 2 | 0 | University College, LondonOTHER | 0 | Aug 17, 2021 | clinicaltrials |
| NCT04094766 | Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia | withdrawn | Phase 1 | 0 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Nov 5, 2020 | clinicaltrials |
| NCT04230330 | Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma | withdrawn | Phase 1 | 0 | National Cancer Centre, SingaporeOTHER | 1 | Nov 5, 2020 | clinicaltrials |
| NCT03553914 | PLM60 for Peripheral T Cell Lymphoma (PTCL) | withdrawn | Phase 1 / Phase 2 | 0 | Conjupro Biotherapeutics, Inc.INDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02786485 | Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT | withdrawn | Phase 1 | 0 | Bellicum PharmaceuticalsINDUSTRY | 0 | Oct 5, 2020 | clinicaltrials |
| NCT03925428 | Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Sep 28, 2020 | clinicaltrials |
| NCT01460602 | Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Louisiana State University Health Sciences Center ShreveportOTHER | 1 | Sep 1, 2020 | clinicaltrials |
| NCT04355039 | INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma | withdrawn | Phase 1 | 0 | Medical College of WisconsinOTHER | 0 | Aug 19, 2020 | clinicaltrials |
| NCT04233697 | Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma | withdrawn | Phase 1 | 0 | Columbia UniversityOTHER | 0 | Aug 13, 2020 | clinicaltrials |
| NCT03506802 | TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma(NYSCT MM) | withdrawn | Phase 1 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT03617224 | Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary Syndrome | withdrawn | Phase 1 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Apr 22, 2020 | clinicaltrials |
| NCT04043845 | ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | withdrawn | Phase 1 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Feb 5, 2020 | clinicaltrials |
| NCT03579927 | CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 29, 2020 | clinicaltrials |
| NCT01789723 | Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn | withdrawn | Phase 1 | 0 | Acrotech Biopharma Inc.INDUSTRY | 0 | Jan 23, 2020 | clinicaltrials |
| NCT01415765 | MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Dec 17, 2019 | clinicaltrials |
| NCT02729961 | Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | University of WashingtonOTHER | 1 | Oct 10, 2019 | clinicaltrials |
| NCT03657420 | Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma | withdrawn | Phase 1 | 0 | Massachusetts General HospitalOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT03373305 | Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 1 | Apr 30, 2019 | clinicaltrials |
| NCT03856112 | Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Mar 26, 2019 | clinicaltrials |
| NCT02657447 | Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02) | withdrawn | Phase 1 | 0 | Nordic NanovectorINDUSTRY | 1 | Jan 10, 2019 | clinicaltrials |
| NCT02378922 | Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Dec 27, 2018 | clinicaltrials |
| NCT03349346 | Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents | withdrawn | Phase 1 | 0 | Gilead SciencesINDUSTRY | 4 | Dec 11, 2018 | clinicaltrials |
| NCT02343666 | HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 20, 2018 | clinicaltrials |
| NCT02228512 | Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Aug 31, 2018 | clinicaltrials |
| NCT03369964 | A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | withdrawn | Phase 1 | 0 | Hoffmann-La RocheINDUSTRY | 1 | Apr 5, 2018 | clinicaltrials |
| NCT03205891 | Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 17, 2018 | clinicaltrials |
| NCT02875002 | Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas | withdrawn | Phase 1 | 0 | Yale UniversityOTHER | 1 | Dec 22, 2017 | clinicaltrials |
| NCT03100877 | Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | City of Hope Medical CenterOTHER | 1 | Dec 13, 2017 | clinicaltrials |
| NCT02229981 | Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma(ABC-102) | withdrawn | Phase 1 / Phase 2 | 0 | RedHill Biopharma LimitedINDUSTRY | 1 | Dec 7, 2017 | clinicaltrials |
| NCT01163201 | T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT03283046 | Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Sep 20, 2017 | clinicaltrials |
| NCT02677948 | Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | withdrawn | Phase 1 / Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Sep 6, 2017 | clinicaltrials |
| NCT03191981 | Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma(MUKfourteen) | withdrawn | Phase 1 / Phase 2 | 0 | University of LeedsOTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT02658396 | GO-203-2C + Bortezomib For Relapsed Or Refractory MM | withdrawn | Phase 1 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 5, 2017 | clinicaltrials |
| NCT02408042 | Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) | withdrawn | Phase 1 / Phase 2 | 0 | Western Regional Medical CenterOTHER | 1 | Jun 27, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Jan 13, 2023source: clinicaltrials